Loading peptide profile…
Loading peptide profile…
Metabolic Category
THE HUNGER DRIVER
Growth Hormone Releasing Peptide-6
GHRP-6 is a synthetic peptide in the ghrelin receptor agonist family. A small human study measured growth hormone and IGF-1 responses. It is not FDA approved.
Hard gainers who struggle to eat enough · Bodybuilders in bulking phases · Those wanting GH boost with appetite increase · Athletes recovering from injury · Anyone needing appetite stimulation
100-300 mcg 2-3 times daily
8-12 weeks on, 4 weeks off
Clinical team guidance, not medical advice.
Based on what vendors sell, not a recommendation.
Injection
Sold as vials by 49 vendors
By mouth
Not sold by vendors we track
Nasal spray
Not sold by vendors we track
Not FDA approved, research use onlyHow we review these guides13 research sources
In nine healthy men, GHRP-6 increased growth hormone pulse size and circulating IGF-1. This did not test muscle gain or recovery.
This peptide family acts at the ghrelin receptor, which participates in growth hormone release.
Produces intense hunger through hypothalamic activation
GHRP-6 is a synthetic chain of six amino acids. Bowers and colleagues described its sequence in a 1984 paper as His-D-Trp-Ala-Trp-D-Phe-Lys-NH2. The D designations identify the configuration of particular amino-acid residues, while NH2 denotes an amidated end. The paper is part of the early laboratory history of the growth-hormone-releasing peptide family.
[Bowers and colleagues' hexapeptide study, 1984](https://pubmed.ncbi.nlm.nih.gov/6714155/)
No. This profile records GHRP-6 as not FDA approved and for research use only. Review the regulatory and source details on this page for the current context.
Dose: 100-300 mcg 2-3 times daily. Schedule: eod. Cycle: 8-12 weeks on, 4 weeks off. This is clinical-team guidance for reference and does not replace individualized instructions from a licensed clinician.
This guide links to 13 curated or current research sources. Inspect the research section and the citations beneath the research answers for their supporting sources.
Review the GHRP-6 research sourcesWe don't list specific side effects for GHRP-6.
GHRP-6 has an editorial safety grade of B (Good Safety). Human safety evidence is limited. The FDA identifies concerns about reduced insulin sensitivity, higher blood glucose and effects on cortisol. Safety depends on dose, sourcing, health history and medical supervision, so this page does not call it safe for personal use.
In the randomized open-label human acute stroke trial, GHRP6 was tested as part of a combined EGF+GHRP6 therapy given twice daily for 7 days to 95 patients, while 93 patients received standard care. In that trial, severe adverse events occurred in 48 of 188 patients, and none were considered treatment-related. These findings are about the combined EGF+GHRP6 therapy in that trial, not about GHRP6 given alone.
In-stock prices from 48 vendors, checked Nov 7, 2026.
Market evidence
We found certificates from some of the GHRP-6 vendors we track. Based on the certificates our crawler found; vendors may publish more than we index. Research on this page describes the molecule. Vendor certificates concern particular market samples or batches; they do not change the research evidence or establish clinical safety, sterility, or suitability for use.
The clinic network
Request a free connection to a peptide clinic, by telehealth or in person. A licensed clinician decides whether any treatment is right for you. What peptide therapy involves
A synthetic ghrelin receptor agonist studied in hormone testing
from $1.92/mg · 71 vendorsNº 003 / 006FDA-approved dual GIP and GLP-1 agonist for diabetes and obesity
from $1.32/mg · 563 vendorsNº 006 / 006Myostatin-trapping fusion protein; development halted over bleeding
from $36.20/mg · 19 vendorsNº 001 / 006A natural protein that restrains skeletal muscle growth
from $105 · 8 vendorsNº 002 / 006A modified IGF-1 analogue used in laboratory research
from $30.10/mg · 149 vendorsNº 004 / 006Ghrelin-mimicking small molecule, investigational and not FDA-approved
Full profileNº 005 / 006